Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay
Authors:
- 1 January 1991
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 27 (4) , 263-270
Abstract
We report the predictive model for the clinical response of new platinum analogs against lung cancer by a bioassay using human lung-cancer cell lines including small-cell (SCLC) and non-small-cell lung cancer (NSCLC). Exponentially growing cells of six different SCLC and sic NSCLC lines were exposed to different concentrations of the three platinum compounds, cisplatin, carboplatin, and 254-S in a double-agar colony-forming cell assay. The concentrations inhibiting 50% of colony formation (IC50 value) for cisplatin, carboplatin and 254-S in SCLC cell lines were significantly lower than those in NSCLC cell lines. A total of 15 patients entered the pharmacological study. In all, 80 mg/m2 cisplatin, 450 mg/m2 carboplatin, and 100 mg/m2 254-S were each given to five patients by intravenous drip infusion. Bioassay as well as chemical assay was achieved by clonogenic techniques using NCI-H-69 (SCLC cell line) and PC-9 (NSCLC cell line) as target cells. Biological comparison of antitumor activity was performed on the basis of the antitumor activity of patients' plasma using the antitumor index (ATI), which was defined as the area under the percentage of colony suppression versus time curve obtained by bioassay and calculated by the trapezoidal rule. When NCI-H-69 and PC-9 were used as target cells for bioassay, colony-inhibitory activity was revealed by the ATIs. The ATIs obtained by bioassay showed better correlation than the AUCs obtained by chemical assay with the clinical response for cisplatin and carboplatin against SCLC and NSCLC, according to the following equation: [Reported Response (%)]=11.5668+0.0014×[ATI] (r=0.97). The response rates for 254-S against SCLC and NSCLC were predicted by this formula to be 40%–65% and 14%–16%, respectively. 254-S is prospectively suspected of having the same, if not more, activity then carboplatin against SCLC and of having almost the same activity as cisplatin against NSCLC.Keywords
This publication has 40 references indexed in Scilit:
- Prediction from Creatinine Clearance of Thrombocytopenia and Recommended Dose in Patients Receiving (Glycolato‐O, O′)‐diammine Platinum (II) (NSC 375101D)Japanese Journal of Cancer Research, 1990
- Pharmacokinetics of (glycolato-0,0?)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatinCancer Chemotherapy and Pharmacology, 1989
- Phase II Study of Carboplatin in Small Cell Lung CancerJapanese Journal of Clinical Oncology, 1988
- Preclinical antitumor and toxicologic profile of carboplatinCancer Treatment Reviews, 1985
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981
- Phase-II study with cis-dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinomaEuropean Journal of Cancer (1965), 1980
- Selection of potential second generation platinum compoundsBiochimie, 1978
- Analysis of platinum in biological materials by flameless atomic absorption spectrophotometryBiochemical Medicine, 1977
- Primary Bioassay of Human Tumor Stem CellsScience, 1977
- Platinum Compounds: a New Class of Potent Antitumour AgentsNature, 1969